MedTrace Logo

Intravenous Microdose Pharmacokinetic (PK) Study With [14C]-GSK2239633

NCT01086462 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2017-07-18

No results posted yet for this study

Summary

This study is a first administration to man microdose study to describe the pharmacokinetics of GSK2239633.

Conditions

Interventions

DRUG

GSK2239633

100 ug GSK2239633 containing approximately 10kBq \[14C\]-GSK2239633

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-01-21
Primary Completion
2010-02-22
Completion
2010-02-22

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01086462 on ClinicalTrials.gov